Navigation Links
The Galien Foundation Announces 2014 Prix Galien USA Nominees for "Best Biotechnology Product," "Best Pharmaceutical Agent," and "Best Medical Technology"

NEW YORK, July 31, 2014 /PRNewswire/ -- The Galien Foundation today announced the 2014 nominees for the eighth annual Prix Galien USA Awards. The Prix Galien Award is considered the biomedical industry's highest accolade and recognizes the technical, scientific and clinical research skills necessary to develop innovative medicines and devices.

This year brings the highest number of nominees since the inception of the Prix Galien USA. Nominees include biomedical products across three categories – biotechnology, pharmaceutical, and technology products – that advance the human condition and which were approved by the U.S. Food and Drug Administration (FDA) during the past five years.

Nominees for the Prix Galien USA 2014 Awards are: Best Biotechnology Product (Nominees)BOTOX® (onabotulinumtoxinA)Allergan, Inc.for Chronic Migraine patientsVoraxaze® (glucarpidase)BTG International Inc.Erwinaze® (asparaginase Erwinia chrysanthemi)

Jazz PharmaceuticalsFluMist® QuadrivalentMedImmune/AstraZeneca(influenza vaccine live, intranasal)HEMACORD (HPC, Cord Blood)New York Blood Center'sHoward P. Milstein Cord Blood CenterFlucelvax® (Influenza Virus Vaccine)

NovartisGattex® (teduglutide)NPS PharmaZaltrap® (ziv-aflibercept)SanofiJetrea® (ocriplasmin)ThromboGenicsBest Pharmaceutical Agent (Nominees)Ampyra® (dalfampridine)Acorda TherapeuticsOpsumit® (macitentan)Actelion Pharmaceuticals LtdOZURDEX®Allergan, Inc(dexamethasone intravitreal implant) 0.7 mgBELIVIQ® (lorcaserin HCl) CIVArena Pharmaceuticals, Inc. & Eisai Inc.Caprelsa® (vandetanib)AstraZenecaAdempas® (riociguat)Bayer HealthCareStivarga® (regorafenib)Bayer HealthCareTecfidera® (dimethyl fumarate)Biogen IdecSovaldi® (sofosbuvir)Gilead SciencesJakafi® (ruxolitinib)IncyteImbruvica® (ibrutinib)Janssen & Pharmacyclics Invokana® (canaglifozin)Janssen SIRTURO® (bedaquiline)JanssenXarelto® (rivaroxaban)Janssen & Bayer HealthCareZytiga® (abiraterone acetate)JanssenXtandi® (enzalutamide)Medivation & AstellasXalkori® (crizotinib)PfizerXeljanz® (tofacitinib)PfizerEliquis® (apixaban)Bristol-Myers Squibb & PfizerOxyContin®Purdue Pharma(reformulated oxycodone HCl controlled release)Latuda® (lurasidone HCI)Sunovion Pharmaceuticals Inc.Neupro® (Rotigotine Transdermal System)UCBVimpat® (lacosamide)UCB Best Medical Technology (Nominees)SERI® Surgical ScaffoldAllergan, Inc.VITEK® MS PlatformbioMérieux COMBIVENT® RESPIMAT®Boehringer Ingelheim(ipratropium bromide and albuterol)Inhalation SprayThe Alair Bronchial Thermoplasty SystemBoston ScientificPrecision Spectra™ Spinal CordBoston ScientificStimulator SystemsuperDimension™ Navigation SystemCovidien – Interventional Lung SolutionsMobi-C® Cervical DiscLDR Holding CorporationNovoTTF™ TherapyNovocurecoflex®  Interlaminar Stabilization™ deviceParadigm Spine, LLCElecsys® Testosterone IIRoche Auvi-Q® (epinephrine injection, USP)SanofiTrevo® ProVue™ RetrieverStrykerCentraSight® Implantable Telescope TechnologyVisionCare Ophthalmic Technologies"Biomedical research can only exist when there are those who are willing to push innovation, extract understanding, and bring attention to the details," remarked Bruno Cohen, Chairman of the Galien Foundation.  "This year's nominees are catalysts for the development of disease-altering advances through biopharmaceutical and medical technology innovation. It is upon these values that the Galien Foundation is predicated, and we're proud to honor those in the field who exemplify these same principles."

The Prix Galien USA Committee, comprised of 10 renowned leaders from the biomedical industry and academia, including five Nobel Laureates, is responsible for evaluating nominees. Winners will be honored at the Prix Galien USA Awards Ceremony on October 28, 2014 at 6:30 p.m., at the American Museum of Natural History in New York City.  Registration for the 2014 Prix Galien USA Awards Ceremony is open and can be accessed here.

Galien Awards Committee 2014

  • Pr Richard Axel, M.D., Nobel Laureate, Co-Director, the Kavli Institute for Brain Science, Columbia University Medical Center, New York.
  • Pr Michael S. Brown, M.D., Nobel Laureate, Professor of Molecular Genetics and Internal Medicine, UT Southwestern Medical Center at Dallas.
  • Pr Laurie Glimcher, M.D., Dean of Weill Cornell Medical College and Provost for Medical Affairs, Cornell University, New York.
  • Pr Joseph Goldstein, M.D., Nobel Laureate, Professor of Molecular Genetics and Internal Medicine, UT, Southwestern Medical Center at Dallas.
  • Pr Robert S. Langer, M.D., David H. Koch Institute Professor at MIT.
  • Pr Paul A. Marks, M.D., Laboratory Head of Cell Biology Memorial Sloan-Kettering Cancer Center, New York. President, Emeritus, MSKCC.
  • Pr Bengt Samuelsson, M.D., Ph.D., Nobel Laureate, Former President of Karolinska Institute and Former Chairman of the Nobel Foundation.
  • Pr Marc Tessier-Lavigne, Ph.D., President and Professor Laboratory of Brain Development and Repair, The Rockefeller University, New York.
  • Pr Roy Vagelos, M.D., Chairman. Chairman of Regeneron Pharmaceuticals and Retired Chairman and Chief Executive Officer of Merck & Co., Inc.
  • Pr Elie Wiesel, Peace Nobel Laureate, Boston University Professor Emeritus. Honorary Member.
  • About the Galien Foundation
    The Galien Foundation fosters, recognizes and rewards excellence in scientific innovation to improve the state of human health. Our vision is to be the catalyst for the development of the next generation of innovative treatment and technologies that will impact human health and save lives.

    The Foundation oversees and directs activities in the USA for the Prix Galien, an international award that recognizes outstanding achievements in improving the human condition through the development of innovative therapies. The Prix Galien was created in France in 1970 in honor of Galen, the father of medical science and modern pharmacology. Worldwide, the Prix Galien is regarded as the equivalent of the Nobel Prize in biopharmaceutical and medical technology research.

    For more information visit

    Logo -

    Galien Foundation Media Contact:
    Bryan Gibbs
    Makovsky on behalf of The Galien Foundation

    SOURCE Galien Foundation
    Copyright©2014 PR Newswire.
    All rights reserved

    Related medicine technology :

    1. The Galien Foundation Announces New "Best Medical Technology" Award Category for 2012 Prix Galien USA Awards Program
    2. The Galien Foundation Announces Roster of Luminary Presenters for Third Galien Forum; Program Highlights Include CEO Panel, Panel on Alzheimers Disease Innovation, Nobel Laureate Elie Wiesel
    3. NIH Director Francis S. Collins, M.D., Ph.D. Selected as 2012 Pro Bono Humanum Honoree by Prix Galien USA
    4. The Galien Foundation Announces 2013 Prix Galien USA Nominees for "Best Biotechnology Product," "Best Pharmaceutical Agent," and "Best Medical Technology"
    5. Boston Scientific Receives Prestigious 2013 Prix Galien Award For Best Medical Technology
    6. American Academy of Family Physicians Foundation Launches Cities for Life
    7. Foundation for Managed Care Pharmacy (FMCP) Presents Awards for 2012 National P&T Competition and Best Posters
    8. Patient Advocate Foundation Announces New Co-Pay Relief (CPR) Offerings for Patients Facing Health Issues Due to Electrolyte Imbalance
    9. Evergreen Healthcare Foundation Gala Raises Nearly $1.1 Million to Benefit Breast Health Center
    10. National Patient Advocate Foundation Praises Signing of the Delaware Cancer Treatment Access Act into Law
    11. Michael J. Fox Foundation-Funded Study Identifies Best Dyskinesia Clinical Rating Scale
    Post Your Comments:
    (Date:6/23/2016)... , June 23, 2016 Any dentist who has ... of the current process. Many of them do not even ... technical difficulties and high laboratory costs involved. And those who ... it at such a high cost that the majority of ... Dr. Parsa Zadeh , founder of Dental Evolutions ...
    (Date:6/23/2016)... Roche (SIX: RO, ROG; OTCQX: RHHBY) announced that it ... (procalcitonin) assay as a dedicated testing solution for people ... Roche is the first IVD company in the U.S ... assessment and management. PCT is a sepsis-specific ... blood can aid clinicians in assessing the risk of ...
    (Date:6/23/2016)... DUBLIN , June 23, 2016 ... "Key Pharma News Issue 52" report to their offering. ... need in influenza treatment creates a favourable commercial environment for ... and growing patient base that will serve to drive considerable ... flu vaccine would serve to cap sales considerably, but development ...
    Breaking Medicine Technology:
    (Date:6/27/2016)... ... ... TherapySites, the leading website and online marketing ... Association. This new relationship allows TherapySites to continue to extend their online ... and promotional offers. , "TCA is extremely excited about this new partnership, as ...
    (Date:6/26/2016)... ... June 26, 2016 , ... On June 10-11, 2016, A Forever ... Cereal Festival and World’s Longest Breakfast Table in Battle Creek, MI, where the rehabilitation ... as home to some of the world’s leading providers of cereal and other breakfast ...
    (Date:6/25/2016)... D.C. (PRWEB) , ... June 25, 2016 , ... ... discuss health policy issues and applications at AcademyHealth’s Annual Research Meeting June 26-28, ... their work on several important health care topics including advance care planning, healthcare ...
    (Date:6/25/2016)... ... June 25, 2016 , ... As a lifelong Southern Californian, ... and his M.D from the David Geffen School of Medicine at UCLA. He trained ... Angeles to complete his fellowship in hematology/oncology at the UCLA-Olive View-Cedars Sinai program where ...
    (Date:6/24/2016)... ... June 24, 2016 , ... Those who have experienced traumatic events ... turn to unhealthy avenues, such as drug or alcohol abuse, as a coping mechanism. ... tools for healthy coping following a traumatic event. , Trauma sufferers tend to feel ...
    Breaking Medicine News(10 mins):